Study Evaluating EKB-569 in Advanced Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2005-01-01
Target enrollment:
Participant gender:
Summary
This non-randomized, open-label, outpatient clinical trial is designed to assess the safety
and efficacy of daily orally administered EKB-569 in subjects with advanced non-small cell
lung cancer. Patients must have been previously treated with a platinum- and docetaxel-based
therapy either given concurrently or as separate regimens.
The primary objective of the study is to assess the clinical activity of EKB-569 administered
orally as a second-line or later stage treatment in subjects with advanced non-small cell
lung cancer. Secondary objectives include:
- To further evaluate the safety of EKB-569
- To explore additional clinical activity parameters
- To explore subject survival
- To evaluate the pharmacokinetics of EKB-569
- To assess subject reported outcomes
EKB-569 will be administered orally as a single-agent. Eligible subjects will take EKB-569
daily as long as they do not have progressive disease and are tolerating treatment.